Search / 120 results found

  • Updated

MORRISVILLE, N.C., June 3, 2021 /PRNewswire/ -- Q2 Solutions and MindX Sciences Inc., a company that works to improve lives through empowering precision medicine approaches to mental health,  today announced a partnership, where Q2 Solutions will be conducting genomics laboratory testing services for MindX Sciences blood tests. Initial tests offered by MindX will include mood disorders, such as depression and bipolar disorder, as well as pain, post-traumatic stress disorder (PTSD), suicidality, memory disorders, and longevity.

  • Updated

DURHAM, N.C., May 26, 2021 /PRNewswire/ -- Inhalon Biopharma, a start-up immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating a variety of acute respiratory infections (ARI), today announced that it has been awarded a $7 million contract by the U.S. Army Medical Research & Development Command (USAMRDC) to conduct a placebo-controlled Phase 1/2a study of IN-006 in COVID-19 outpatients. IN-006 is a potent, neutralizing monoclonal antibody being investigated for the treatment of COVID-19. Initial results of this study are expected in 2022.